LAVA Therapeutics NV

LAVA Therapeutics NV — Investor Presentation (April 2023)

45 slides from LAVA Therapeutics NV's investor presentation, Apr 24, 2023

  1. Slide 1: Gamma delta T cell engagers for next-generation cancer therapeutics

    Gamma delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation April 2023

  2. Slide 2: Legal Disclosure: Forward-looking Statements

    Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expe

  3. Slide 3: Pioneering Next-Generation Cancer Therapeutics

    Pioneering Next-Generation Cancer Therapeutics ©LAVA Therapeutics 2023 3 • Bispecific antibody platform to engage Vγ9Vδ2 T cells for highly specific tumor cell killing – Leverage the unique quality of Vγ9Vδ2 T cells to selectively kill tumor cells while sparing normal cells – Fully modular approach

  4. Slide 4: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications

    MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer Gammabody™ Pipeline: Potential in Hematological and Solid Tumor Indications 4 Cand

  5. Slide 5: Team Led by Experienced Leaders in the Biotech and Pharma Field

    Ton Adang, PhD CDO • Vast experience in drug development • Extensive experience in product discovery and project management (e.g., KEYTRUDA) HansvanderVliet,MD,PhD CSO • Inventor of LAVA’s gamma delta T cell engager platform • Medical oncologist, extensive experience in pre-clinical and clinical res

  6. Slide 6: LAVA's Proprietary Gammabody Platform

    LAVA’s Proprietary Gammabody™ Platform Bispecific Gamma Delta T Cell Engagers

  7. Slide 7: Bispecific antibodies entering the clinic by year

    Source: The Antibody Society Data as of Apr 14, 2023 ©LAVA Therapeutics 2023 1 0 1 0 3 1 0 0 0 1 6 4 5 5 10 16 17 21 35 45 31 65 59 7 0 10 20 30 40 50 60 70 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 catumaxomab (malignant

  8. Slide 8: Enthusiasm for Bispecific T Cell Engagers

    • High expectations for targeted T cell therapies in cancer, but often: – Narrow therapeutic window: – Cytokine Release Syndrome – On-target/off-tumor-related toxicities – Activates immunosuppressive T cells – Sporadic efficacy in solid tumors therapeutic window therapeutic effect toxic effect ©LAVA

  9. Slide 9: Strategies for Widening the Therapeutic Window

    • Selecting ‘tumor-specific’ targets • Step-dosing / subcutaneous dosing • Decreasing affinity for T cells • Masking/site-specific activation • Recruiting alternative effector cells • Address only narrow target range, and/or • Cumbersome, and/or • Strongly decrease potency ©LAVA Therapeutics 2023 9

  10. Slide 10: Gammabody Platform: Bispecific γδ T Cell Engagers

    Gammabody™ Platform: Bispecific γδ T Cell Engagers DIFFERENTIAL APPROACH A versatile bispecific antibody platform for developing novel cancer therapeutics MECHANISM OF ACTION LAVA's proprietary bispecific antibodies are designed to: – Target Vγ9Vδ2 T cells to tumor antigens initiating selective tumo

  11. Slide 11: Bispecific γδ T cell-engagers harness innate and adaptive immunity

    Bispecific γδ T cell-engagers aim to harness innate & adaptive immunity • Largest γδ-T cell subset in blood: (~90-95% of total γδ-T cells) • Natural ability to recognize and kill tumor cells • Highly cytotoxic • Relatively abundant in tumor-infiltrating lymphocytes • Presence of γδ T cells associate

  12. Slide 12: Off-the-Shelf Gammabody Platform Directs Vγ9Vδ2 T Cells to Cancer Cells

    Off-the-Shelf Gammabody™ Platform: Enhances Innate Tumor Recognition by Directing Vγ9Vδ2 T Cells to the Cancer Cells LAVA’s Gammabody™ directs Vγ9Vδ2 T cells to tumors with high affinity to induce direct tumor cell killing and orchestrate an immunological cascade of anti-cancer responses and while r

  13. Slide 13: Cascade of Anti-Cancer Responses and Favorable Therapeutic Window

    Cascade of Anti-Cancer Responses – Potential Translation to Favorable Therapeutic Window Efficacy: • Potent killing of cancer cells (EC50s in the low picomolar range) • No co-activation of immune-suppressive Tregs which dampen antitumor efficacy of cytotoxic T cells • Orchestrate innate and adaptive

  14. Slide 14: Expansion and Cascade Response Without Treg Activation in Preclinical Models

    Gammabody™ can induce robust gamma delta T cell expansion and can amplify the anti-tumor immune response via downstream activation of other immune cells while avoiding co-activation of immunosuppressive T cells such as Tregs Expansion Cascade Response No Treg Activation Gammabody™ - Mediated Expansi

  15. Slide 15: Gammabody Selectively Kills Cancer Cells While Sparing Healthy Cells

    Gammabody™ Can Selectively Kill Cancer Cells While Sparing Healthy Cells in Hematologic Malignancy and Solid Tumor models • 2:1 ratio ( T cells : Target cells) • Similar CD20 expression levels on C1R neo and B-cells CD20 Gammabody™ Mediated Killing PSMA Gammabody™ Mediated Killing Preferential kil

  16. Slide 16: Non-Clinical Safety Data Indicate Good Tolerability

    Non-Clinical Safety Data Indicate Good Tolerability • Non-clinical safety studies using Gammabody™ molecules designed for cross-reactivity support the benign safety profile of the platform • NHP studies completed with Gammabody™ molecules targeting CD1d, CD20 and EGFR – CD1d, CD20 targeting surrogat

  17. Slide 17: Gammabody Platform: A Novel T cell engager approach for cancer therapy

    Gammabody™ Platform: A Novel T cell engager approach for cancer therapy γδ T cell engager platform • Highly potent (kills at picomolar concentrations) • Recruits additional immune effector cells by antigen presentation and cascade response • No activation of regulatory T-cells • Tumor-cell selective

  18. Slide 18: LAVA-051 Targets CD1d for CLL, MM & AML

    LAVA-051 Targets CD1d to Activate Vγ9Vδ2 T Cells and iNKT Cells for the Potential Treatment of CLL, MM & AML

  19. Slide 19: LAVA-051: First-in-Class Gammabody Targeting CD1d

    Format • Humanized bispecific single domain antibody (bsVHH) of 27kDa ‒ Short plasma half-life, prolonged functional half-life through high affinity TCR binding Mechanism of Action • Engages Vγ9Vδ2 T cells to mediate potent killing of CD1d-expressing tumor cells – Activates iNKT cells to mediate kil

  20. Slide 20: LAVA-051: Pre-Clinical Data Support Mechanism of Action and Function

    LAVA-051: Pre-Clinical Data Support Mechanism of Action and Function 20 Expansion of Vγ9Vδ2 T and iNKT cells Lysis of patient tumor cells Adapted from Lameris et al., submitted Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 0 20 40 60 80 100 CLL specific lysis (relative %) 0 20 40 60 80

  21. Slide 21: LAVA-051 Phase 1/2a in Hematological Malignancies

    LAVA-051 Phase 1/2a in Hematological Malignancies • Primary objectives: investigate safety and tolerability of LAVA-051 and determine the recommended Phase 2 dose • Secondary objectives: include evaluation of PK, PD, immunogenicity and preliminary antitumor activity • LAVA-051 administered as 2-hour

  22. Slide 22: LAVA-051 Initial Phase Data - Safety

    LAVA-051 – Initial Phase 1 Data - Safety • LAVA-051 has reached a dose of 200 mg (~400x the starting dose) in MM and CLL patients • Most observed AEs have not been suspected to be related • Frequency and severity of AEs have not correlated with increasing dose levels • No CRS and no ICANS (ASTCT) an

  23. Slide 23: LAVA-051 Initial Phase Data - Pharmacodynamics

    23 LAVA-051 – Initial Phase 1 Data – Pharmacodynamics • Pharmacodynamic parameters reflect changes expected for the LAVA-051 mechanism of action – Vγ9Vδ2-T cell activation markers (CD25 and CD69) upregulated following dosing – Maximum Vγ9Vδ2 T cell receptor occupancy (RO) increased with dose ASCO 20

  24. Slide 24: LAVA-051 - Pharmacokinetics

    24 LAVA-051 – Pharmacokinetics ASH 2022 abstract #2014 Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 Pharmacokinetics 1st dose IV, 2nd dose SC patient 32-001 cohort #5  IV  SC  IV • Linear LAVA-051 pharmacokinetics • SC bioavailability 74% compared to IV (based on data from Pt 32-00

  25. Slide 25: LAVA-051 Patient Characteristics and Time on Treatment

    LAVA-051 – Initial Phase 1 Data - Patient Characteristics and Time on Treatment MM/CLL 6/6 Male/Female 8/4 Median age (range) 69 (59-76) Prior therapies, median (range) – MM/CLL 4 (3-5) / 5.5 (4-13) ASH 2022 abstract #2014, corrected Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 25 Dat

  26. Slide 26: LAVA-051 Potential Signs of Activity

    LAVA-051 – Initial Phase 1 Data - Potential Signs of Activity CLL • Patient with R/R CLL (15 mg) • Temporary enlargement and tenderness of several involved lymph nodes accompanied by grade 2 fever during Cycle 1 ‒ Resembled a tumor-flare reaction, as reported in CLL with lenalidomide • Patient asses

  27. Slide 27: LAVA-051: Summary of Initial Phase Data Presented

    LAVA-051: Summary of Initial Phase 1 Data Presented • LAVA-051 is a next-generation bispecific γδ T cell engager designed for a broad therapeutic window • LAVA-051 has reached a dose of 200 mg (400x the starting dose) in MM and CLL patients – Most observed Adverse Events (AEs) have not been suspecte

  28. Slide 28: LAVA-1207: PSMA-targeting Gammabody for mCRPC

    LAVA-1207 Gammabody™ that Activates Vγ9Vδ2 T Cells by Targeting PSMA for the Treatment of mCRPC

  29. Slide 29: LAVA-1207: PSMA-targeting Gammabody for Prostate Cancer

    LAVA-1207: PSMA-targeting Gammabody™ for Prostate Cancer Format • Contains a Fc domain for extended plasma half-life; silenced to avoid off-target T cell activation • Small size (compared to regular IgG antibodies) to facilitate tumor penetration Mechanism of Action • Specifically directs Vγ9Vδ2 T c

  30. Slide 30: LAVA-1207: Preclinical Data Support Activity and Selectivity in Patient Samples

    LAVA-1207: Preclinical Data Support Activity and Selectivity in Patient Samples • LAVA-1207 triggers activation of autologous Vγ9Vδ2 T cells in the presence of patient-derived tumor cells • LAVA-1207 induces selective tumor cell lysis Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 30 Me

  31. Slide 31: LAVA-1207 Phase 1/2a Study Design

    LAVA-1207 – Phase1/2a Study Design 31 • Dose escalation in patients with mCRPC (EudraCT 2021-001789-39; NCT05369000) • Primary objectives: investigate safety and tolerability of LAVA-1207 • Secondary objectives: evaluate PK, PD, immunogenicity and preliminary signs of antitumor activity • LAVA-1207

  32. Slide 32: LAVA-1207 Patient Baseline Characteristics

    LAVA-1207 – Patient Baseline Characteristics 32 N=20 Age, median (range) 68 (51-76) Years since diagnosis, median (range) 9 (3-21) Prior systemic therapies, median (range) 4 (3-10) Location of metastases Bone 19 Lymph node 14 Lung 2 Liver 5 Other visceral 2 Type of progression PSA 17 Bone 12 Nodal 1

  33. Slide 33: LAVA-1207 Time on Treatment

    LAVA-1207 – Time on Treatment ASCO GU 2023 abstract #153 Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 33 • A dose level (DL) of 120 µg (starting dose, 1.5 µg, MABEL approach) completed – DL 1 included 6 pts, 3 from EU, 3 from US; DL 2 included 5 pts, 3 from EU, 2 from US • A total of

  34. Slide 34: LAVA-1207 Initial Phase Data - Safety

    LAVA-1207 – Initial Phase 1 Data - Safety 34 • Most observed AEs not suspected to be related and no DLT • Treatment emergent AEs (TEAEs) that were suspected to be related were grade 1 or 2 • No CRS greater than grade 2 • No increase in severity or frequency of TEAEs with increasing doses and no pati

  35. Slide 35: LAVA-1207 Pharmacokinetics

    LAVA-1207 – Pharmacokinetics • Pharmacokinetics of LAVA-1207 appears linear 35 0 24 48 72 96 120 144 168 1,000 10,000 Dose level 4 Time since infusion start (h) LAVA-1207 (ng/L) 5000 N303 N304 N305 0 24 48 72 96 120 144 168 1,000 10,000 Dose level 5 Time since infusion start (h) LAVA-1207 (ng/L) 30,

  36. Slide 36: LAVA-1207 Pharmacodynamics

    LAVA-1207 – Pharmacodynamics • Pharmacodynamics reflect changes expected as per MoA • Pronounced drop in Vγ9Vδ2-T cell frequency 2 hr after dosing, suggesting Vγ9Vδ2-T cell re-distribution, with subsequent recovery • Vγ9Vδ2-T cell activation markers (CD25 and CD69) upregulated following dosing • Rec

  37. Slide 37: LAVA-1207 Preliminary Signs of Antitumor Activity

    LAVA-1207 – Preliminary Signs of Antitumor Activity 37 Out of 14 iRECIST evaluable patients, 8 had iSD at week 8 Patient N304 – 40 mg • Largest overall decrease in PSA was 61% (46% vs baseline) • Per treating physician, the patient improved clinically with improvement in pain and fatigue • Ongoing i

  38. Slide 38: Summary of Initial Phase Data Presented

    Summary of Initial Phase 1 Data Presented • LAVA-1207 is a PSMA targeting bispecific antibody belonging to a novel class of γδ T cell engagers (Gammabody™) • LAVA-1207 has reached a dose of 120 mg (starting dose 1.5 mg) without the occurrence of high-grade (>2) CRS or DLTs in therapy refractory mCRP

  39. Slide 39: SGN-EGFRd2 (LAVA-1223) Licensed to Seagen

    SGN-EGFRd2 (LAVA-1223) – Licensed to Seagen Gammabody™ for the treatment of EGFR-expressing solid tumors

  40. Slide 40: SGN-EGFRd2 (LAVA-1223) EGFR-Targeting Gammabody

    SGN-EGFRd2 (LAVA-1223) – EGFR-Targeting Gammabody™ Format • Gammabody™ format containing a silenced Fc domain Mechanism of Action • Induces preferential lysis of EGFR-expressing tumor cells while relatively sparing EGFR-expressing normal cells Status • Exclusive worldwide license agreement with Seag

  41. Slide 41: LAVA-1266: CD123 Targeting Gammabody

    CD123 Targeting Gammabody™ for the Treatment of Hematologic Malignancies LAVA-1266

  42. Slide 42: LAVA-1266: CD123-Targeting Gammabody for Hematological Malignancies

    Mechanism of Action • Induces preferential lysis of CD123-expressing tumor cells while relatively sparing CD123-expressing normal cells – CD123 is overexpressed in a wide range of hematological malignancies Status • CTA/IND enabling studies ongoing; filing anticipated in 2024 LAVA-1266: CD123-Target

  43. Slide 43: Milestones

    Milestones

  44. Slide 44: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications

    MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer Gammabody™ Pipeline: Potential in Hematological and Solid Tumor Indications 44 Can

  45. Slide 45: Gamma delta T cell engagers for next-generation cancer therapeutics

    Gamma delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation April 2023

LAVA Therapeutics — Investor Presentation (April 2023) on 6ix